March 28, 2026 15:00 ET | Source: Roivant Sciences The results of the Phase 3 VALOR trial were published in…
“Persistent kidney inflammation is a hallmark of IgAN, and a key driver of disease progression, leading to ongoing kidney damage…
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease…
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in…
Study Confirms Long-Acting Treatment is Effective among People Living with HIV Who Experience Challenges Taking Daily Oral Treatment February 18,…
New Identity Reflects Patient-First Philosophy, Practice Growth Board-Certified Spine Surgeon Joins Growing Central Jersey Practice OLD BRIDGE, N.J., Feb. 10,…
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the…
DUBAI, United Arab Emirates, Jan. 31, 2026 (GLOBE NEWSWIRE) -- Building on the unprecedented success of its 2025 Masterclass, AEON…
ALLENTOWN, Pa., Jan. 26, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine continues its tradition of community giving by empowering employees…
Erie, PA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Medical education is often delivered through a single instructional format, but Lake…